GLG News by CPAP Device Prescribers (US)
Request a free trial
November 17, 2008"Tamper-Proof" -- A Significant Gain to Whom??
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic.
Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
June 17, 2008
Bottle Feeding, Teething & Seething Toxins
Analysis of: FDA's Chief Scientist Asks Science Board Subcommittee To Review Research On Bisphenol-A | www.medicalnewstoday.com
Author: GLG Expert Contributor
Analysis of: FDA's Chief Scientist Asks Science Board Subcommittee To Review Research On Bisphenol-A | www.medicalnewstoday.com
Author: GLG Expert Contributor
Parents never gave plastic a second thought that these seemingly safe vessels are capable of destroying, altering, and risking our children's internal building blocks of life. Babies used to be nursed with glass bottles that were capable of being sterilized,...
June 17, 2008
Bottle Feeding, Teething & Seething Toxins
Analysis of: FDA's Chief Scientist Asks Science Board Subcommittee To Review Research On Bisphenol-A | www.medicalnewstoday.com
Author: GLG Expert Contributor
Analysis of: FDA's Chief Scientist Asks Science Board Subcommittee To Review Research On Bisphenol-A | www.medicalnewstoday.com
Author: GLG Expert Contributor
Babies used to be nursed with glass bottles that were capable of being sterilized, but along with disposable diapers, wet wipes, and gourmet babyfood, the plastic industry presides to contain our infants nutritional and bathing essentials. Parents never gave plastic a second...
June 5, 2008Novartis and Multiple Sclerosis: A Major Commitment
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Extavia, Novartis' brand of interferon beta 1b, has been approved for the treatment of multiple sclerosis by the European Union. With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009. While essentially identical to Bayer's Betaferon interferon beta 1b,...
June 2, 2008Abbott's ABT-089 --Much More than a Treatment for ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD. The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
April 24, 2008COPAXONE from the START of MS
Analysis of: Teva Seeks Approval for the Extension of its Indication to Include the Treatment of Patients with a First Clinical Event Suggestive of MS | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Copaxone has become the leading treatment for relapsing remitting MS in the US. The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.
February 15, 2008Win for Talecris' Gamunex IVIG in Inflammatory Polyneuropathy
Analysis of: Positive Results from Phase III Trial of Gamunex in Patients with CIDP | pharmalive.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Talecris' form of IVIG, Gamunex was studied in the largest trial of IVIG in chronic inflammatory polyradiculoneuropathy (CIDP), with more than twice as many patients moving into remission. CIDP is a common acquired autoimmune peripheral neuropathy, which if not treated, may lead to a peripheral...
February 4, 2008SILENOR -- A Sleeper among Hypnotics
Analysis of: Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Somaxon Pharmaceuticals has submitted a NDA for Silenor for the treatment of insomnia. The active ingredient is doxepin, which has been available for years.The effect of the drug can be expected to be very modest, side effects unfavorable when compared to Ambien or Lunesta, and with both significant...
January 18, 2008Major Win For Glaxo with Xenoport for Restless Legs syndrome -- Next Blockbuster?
Analysis of: GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262 | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3 trial, should be a major win in the marketplace. RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.
September 19, 2007
Exciting Prospect for Alternative Treatment of COPD and asthma
Analysis of: Newly Discovered Fatty Acids May Lead To Novel Treatments For COPD And Asthma | www.medicalnewstoday.com
Author: Warren Botnick, President, PSS Clinical Research
Exciting Prospect for Alternative Treatment of COPD and asthma
Analysis of: Newly Discovered Fatty Acids May Lead To Novel Treatments For COPD And Asthma | www.medicalnewstoday.com
Author: Warren Botnick, President, PSS Clinical Research
Eicosanoids appear promising in the treatment of such airways diseases as COPD and asthma, which affect millions worldwide. Any alternative to current anti-inflammatory therapy, which consists almost entirely of forms of corticosteroids, would almost certainly be welcomed and adopted in widespread...
Page : 1 2 Next1 to 10 of 16
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

